These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 15127370)
1. Quinolone resistance among pneumococci: therapeutic and diagnostic implications. Low DE Clin Infect Dis; 2004 May; 38 Suppl 4():S357-62. PubMed ID: 15127370 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae. Jones RN; Fritsche TR; Sader HS Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501 [TBL] [Abstract][Full Text] [Related]
3. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae. Jones RN; Sader HS; Stilwell MG; Fritsche TR Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904 [TBL] [Abstract][Full Text] [Related]
4. Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae. Schurek KN; Adam HJ; Hoban DJ; Zhanel GG Int J Antimicrob Agents; 2006 Sep; 28(3):266-9. PubMed ID: 16904294 [TBL] [Abstract][Full Text] [Related]
5. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Anderson KB; Tan JS; File TM; DiPersio JR; Willey BM; Low DE Clin Infect Dis; 2003 Aug; 37(3):376-81. PubMed ID: 12884162 [TBL] [Abstract][Full Text] [Related]
6. Resistance of Streptococcus pneumoniae to fluoroquinolones--United States, 1995-1999. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2001 Sep; 50(37):800-4. PubMed ID: 11785571 [TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. Feldman C J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171 [TBL] [Abstract][Full Text] [Related]
8. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance. Ferrara AM Infection; 2005 Jun; 33(3):106-14. PubMed ID: 15940410 [TBL] [Abstract][Full Text] [Related]
9. Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004). Deshpande LM; Sader HS; Debbia E; Nicoletti G; Fadda G; Jones RN; Diagn Microbiol Infect Dis; 2006 Mar; 54(3):157-64. PubMed ID: 16423493 [TBL] [Abstract][Full Text] [Related]
10. Penicillin and macrolide resistance in pneumococcal pneumonia: does in vitro resistance affect clinical outcomes? Rothermel CD Clin Infect Dis; 2004 May; 38 Suppl 4():S346-9. PubMed ID: 15127368 [TBL] [Abstract][Full Text] [Related]
11. In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease. Pérez-Trallero E; Marimón JM; González A; Ercibengoa M; Larruskain J Clin Infect Dis; 2005 Aug; 41(4):560-4. PubMed ID: 16028169 [TBL] [Abstract][Full Text] [Related]
12. Activity of the new quinolone WCK 771 against pneumococci. Appelbaum PC; Pankuch GA; Bozdogan B; Lin G; Jacobs MR; Patel MV; Gupte SV; Jafri MA; De Souza NJ; Khorakiwala HF Clin Microbiol Infect; 2005 Jan; 11(1):9-14. PubMed ID: 15649298 [TBL] [Abstract][Full Text] [Related]
13. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Fuller JD; Low DE Clin Infect Dis; 2005 Jul; 41(1):118-21. PubMed ID: 15937772 [TBL] [Abstract][Full Text] [Related]
14. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003). Johnson DM; Stilwell MG; Fritsche TR; Jones RN Diagn Microbiol Infect Dis; 2006 Sep; 56(1):69-74. PubMed ID: 16546341 [TBL] [Abstract][Full Text] [Related]
15. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. Ross JJ; Worthington MG; Gorbach SL N Engl J Med; 2002 Jul; 347(1):65-7; author reply 65-7. PubMed ID: 12097545 [No Abstract] [Full Text] [Related]
17. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae. Louie A; Brown DL; Liu W; Kulawy RW; Deziel MR; Drusano GL Antimicrob Agents Chemother; 2007 Nov; 51(11):3988-4000. PubMed ID: 17846144 [TBL] [Abstract][Full Text] [Related]
18. In vitro activity of quinolones against S. pneumoniae, H. influenzae and M. catarrhalis in Saudi Arabia. Balkhy HH; Memish ZA; Shibl A; Elbashier A; Osoba A East Mediterr Health J; 2005; 11(1-2):36-44. PubMed ID: 16532669 [TBL] [Abstract][Full Text] [Related]
19. Emergence of fluoroquinolone-resistant Streptococcus pneumoniae in Lebanon: a report of three cases. Naba MR; Araj GF; Baban TA; Tabbarah ZA; Awar GN; Kanj SS J Infect Public Health; 2010; 3(3):113-7. PubMed ID: 20869671 [TBL] [Abstract][Full Text] [Related]
20. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. Jones RN; Fritsche TR; Sader HS; Stilwell MG Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]